568 related articles for article (PubMed ID: 27256364)
41. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.
Sun N; Zhao H
Biotechnol Bioeng; 2014 May; 111(5):1048-53. PubMed ID: 23928856
[TBL] [Abstract][Full Text] [Related]
42. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency.
Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G
Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786
[TBL] [Abstract][Full Text] [Related]
43. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
44. Induced Pluripotent Stem Cells Meet Genome Editing.
Hockemeyer D; Jaenisch R
Cell Stem Cell; 2016 May; 18(5):573-86. PubMed ID: 27152442
[TBL] [Abstract][Full Text] [Related]
45. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.
Xie F; Ye L; Chang JC; Beyer AI; Wang J; Muench MO; Kan YW
Genome Res; 2014 Sep; 24(9):1526-33. PubMed ID: 25096406
[TBL] [Abstract][Full Text] [Related]
46. Modern Genome Editing Technologies in Huntington's Disease Research.
Malankhanova TB; Malakhova AA; Medvedev SP; Zakian SM
J Huntingtons Dis; 2017; 6(1):19-31. PubMed ID: 28128770
[TBL] [Abstract][Full Text] [Related]
47. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
[TBL] [Abstract][Full Text] [Related]
48. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.
Yusa K; Rashid ST; Strick-Marchand H; Varela I; Liu PQ; Paschon DE; Miranda E; Ordóñez A; Hannan NR; Rouhani FJ; Darche S; Alexander G; Marciniak SJ; Fusaki N; Hasegawa M; Holmes MC; Di Santo JP; Lomas DA; Bradley A; Vallier L
Nature; 2011 Oct; 478(7369):391-4. PubMed ID: 21993621
[TBL] [Abstract][Full Text] [Related]
49. Induced pluripotent stem cell modeling of malignant hematopoiesis.
Chao MP; Majeti R
Exp Hematol; 2019 Mar; 71():68-76. PubMed ID: 30659850
[TBL] [Abstract][Full Text] [Related]
50. [Induced pluripotent stem cell technology and its application in disease research].
Cai CY; Meng FL; Rao L; Liu YY; Zhao XL
Yi Chuan; 2020 Nov; 42(11):1042-1061. PubMed ID: 33229312
[TBL] [Abstract][Full Text] [Related]
51. Genetic correction of haemoglobin E in an immortalised haemoglobin E/beta-thalassaemia cell line using the CRISPR/Cas9 system.
Trakarnsanga K; Thongsin N; Metheetrairut C; Tipgomut C; Poldee S; Wattanapanitch M
Sci Rep; 2022 Sep; 12(1):15551. PubMed ID: 36114353
[TBL] [Abstract][Full Text] [Related]
52. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
[TBL] [Abstract][Full Text] [Related]
53. Generating autologous hematopoietic cells from human-induced pluripotent stem cells through ectopic expression of transcription factors.
Hwang Y; Broxmeyer HE; Lee MR
Curr Opin Hematol; 2017 Jul; 24(4):283-288. PubMed ID: 28383341
[TBL] [Abstract][Full Text] [Related]
54. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
[TBL] [Abstract][Full Text] [Related]
55. Personalized Medicine: Cell and Gene Therapy Based on Patient-Specific iPSC-Derived Retinal Pigment Epithelium Cells.
Li Y; Chan L; Nguyen HV; Tsang SH
Adv Exp Med Biol; 2016; 854():549-55. PubMed ID: 26427458
[TBL] [Abstract][Full Text] [Related]
56. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.
Zou J; Mali P; Huang X; Dowey SN; Cheng L
Blood; 2011 Oct; 118(17):4599-608. PubMed ID: 21881051
[TBL] [Abstract][Full Text] [Related]
57. Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies.
McTague A; Rossignoli G; Ferrini A; Barral S; Kurian MA
Front Genome Ed; 2021; 3():630600. PubMed ID: 34713254
[TBL] [Abstract][Full Text] [Related]
58. Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted β-thalassemia patient.
Tubsuwan A; Abed S; Deichmann A; Kardel MD; Bartholomä C; Cheung A; Negre O; Kadri Z; Fucharoen S; von Kalle C; Payen E; Chrétien S; Schmidt M; Eaves CJ; Leboulch P; Maouche-Chrétien L
Stem Cells; 2013 Sep; 31(9):1785-94. PubMed ID: 23712774
[TBL] [Abstract][Full Text] [Related]
59. Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology.
Easley CA
Methods Mol Biol; 2019; 1965():19-34. PubMed ID: 31069666
[TBL] [Abstract][Full Text] [Related]
60. Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases.
Chuang K; Fields MA; Del Priore LV
Yale J Biol Med; 2017 Dec; 90(4):635-642. PubMed ID: 29259527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
